RxDoctor Payments Data

Elizabeth Fletcher

Nurse Practitioner · Camden, NJNPI 1851594758

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $46,653 of the $62,029 with a category attached, or 75.2%. Gilead accounts for 81.5% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $27,171, 6.8 times the $3,990 reported in 2021. Among nurse practitioner clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,029in general payments, 2019–2025

Across 276 payments — averaging $224.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$51K
  • Viiv Healthcare Company$11K
  • Janssen Products, LP$174
  • Johnson & Johnson$160
  • Boehringer Ingelheim$118
  • Merck$46
  • plus $56 from 2 others

What the payments were for

  • Consulting fees$2,0103%
  • Speaking & faculty fees$46,65375%
  • Travel & lodging$6,75011%
  • Food & beverage$6,44210%
  • Education$1740%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,029 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$3,008
Medicare patients
18
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala238$991,750
OdefseyEmtricitab/Rilpiviri/Tenof Ala44$163,443
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$124,523
DovatoDolutegravir Sodium/Lamivudine28$86,081
JulucaDolutegravir/Rilpivirine24$82,237
TriumeqAbacavir/Dolutegravir/Lamivudi20$72,884
DescovyEmtricitabine/Tenofov Alafenam11$23,755
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,465
Albuterol Sulfate HfaAlbuterol Sulfate16$682
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$120
Trazodone Hcl21$62
Zolpidem Tartrate12$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$50,533$1,140,027273 claims
Viiv Healthcare CompanyDovato, Juluca, Triumeq$10,942$241,20272 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →